16,926 results match your criteria Hepatology[Journal]


Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial).

Hepatology 2019 Apr 23. Epub 2019 Apr 23.

NAFLD Research Center, Department of Medicine, La Jolla, California.

Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 (SCD1) inhibitor, has been shown to reduce hepatic-fat content in patients with primary nonalcoholic-fatty-liver-disease (NAFLD), however, its effect in patients with HIV-associated NAFLD is unknown. The ARRIVE trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by MRI-proton-density-fat-fraction (PDFF) ≥5%, were randomized to receive either aramchol 600 mg daily (n=25) or placebo (n=25) for 12 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30674DOI Listing

The gut-liver axis in PSC: Are pathobionts the missing link?

Hepatology 2019 Apr 23. Epub 2019 Apr 23.

Division of Gastroenterology and Hepatology and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.

Primary sclerosing cholangitis (PSC) is characterized by progressive fibrosis around intra- and extrahepatic bile ducts that can progress to cirrhosis and liver failure. There are no regulatory drugs approved for PSC and liver transplantation is the only effective therapy(1). While the concentric accumulation of periductular fibrosis suggests the biliary epithelial cell (cholangiocyte) plays an integral role in disease initiation and/or progression, multiple factors from the gut like microbes and their molecular products, endogenous metabolites like bile acids, and primed immune cells have been hypothesized to play a significant role in the hepatobiliary injury and adverse clinical sequelae in PSC. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30673
Publisher Site
http://dx.doi.org/10.1002/hep.30673DOI Listing
April 2019
1 Read

Incretin-based Therapies for the Management of NAFLD in Patients with Type 2 Diabetes.

Authors:
Kenneth Cusi

Hepatology 2019 Apr 21. Epub 2019 Apr 21.

Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL.

The prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2DM) is believed to be ~70% and that of advanced fibrosis ~20%. Given the magnitude of the problem, there is a real sense of urgency to identify the best pharmacological approach for to treat both diabetes and NASH in this population. Vitamin E is recommended for patients with biopsy-proven NASH without diabetes but did not have similar efficacy in a recent proof-of-concept RCT in patients with T2DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30670DOI Listing

Impaired chylomicron assembly modifies hepatic metabolism through bile acid dependent and transmissible microbial adaptations.

Hepatology 2019 Apr 20. Epub 2019 Apr 20.

Departments of Medicine, Pediatrics, Obstetrics and Gynecology, Surgery and McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, 63110, USA.

The mechanisms by which alterations in intestinal bile acid (BA) metabolism improve systemic glucose tolerance and hepatic metabolic homeostasis are incompletely understood. Here we examined metabolic adaptations in mice with conditional intestinal deletion of the abetalipoproteinemia (ABL) gene microsomal triglyceride transfer protein (Mttp-IKO), which blocks chylomicron assembly and impairs intestinal lipid transport. Mttp-IKO mice exhibit improved hepatic glucose metabolism and augmented insulin signaling, without weight loss. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30669
Publisher Site
http://dx.doi.org/10.1002/hep.30669DOI Listing
April 2019
1 Read

P300 Acetyltransferase is a Cytoplasm-to-Nucleus Shuttle for SMAD2/3 and TAZ Nuclear Transport in TGFβ-stimulated Hepatic Stellate Cells.

Hepatology 2019 Apr 20. Epub 2019 Apr 20.

Tumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Austin, MN, USA.

Nuclear translocation of SMAD2/3, core transcription factors of TGFβ signaling, is critical for hepatic stellate cell (HSC) differentiation into metastasis-promoting myofibroblasts. SMAD2/3 have multiple coactivators, including WW domain-containing transcription regulator protein 1 (WWTR1 or TAZ) and p300 acetyltransferase. In the nucleus, TAZ binds to SMAD2/3 to prevent SMAD2/3 nuclear export. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30668DOI Listing

A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: a Case Report.

Hepatology 2019 Apr 20. Epub 2019 Apr 20.

Corporal Michael J Crescenz VA Medical Center, Pathology, 3900 Woodland Avenue, Philadelphia, Pennsylvania, United States.

Nivolumab, an immune checkpoint inhibitor that acts by preventing programmed-death ligand 1 (PD-L1) from binding to the programmed cell death protein-1 (PD-1) receptor, is utilized to treat a variety of cancers including renal cell carcinoma, non-small cell lung cancer, and metastatic melanoma. Currently, nivolumab is FDA-approved as a second-line treatment for advanced hepatocellular carcinoma (HCC) after showing efficacy in patients who progressed on or were intolerant to sorafenib. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30659
Publisher Site
http://dx.doi.org/10.1002/hep.30659DOI Listing
April 2019
1 Read

Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma via the miR-338-3p/PKM2 axis under hypoxic stress.

Hepatology 2019 Apr 20. Epub 2019 Apr 20.

School of Medicine, Southeast University, No.87, Dingjia Bridge, Nanjing, Jiangsu province, China.

Glucose metabolism reprogramming, which is a well-established characteristic of multiple cancers, demands a higher rate of glycolysis to meet the increasing demands for macromolecular synthesis and to maintain rapid proliferation in a hypoxic environment. However, the mechanism underlying this switch remains to be elucidated. In this study, we investigated the function of circular RNA MAT2B (circMAT2B) in hepatocellular carcinoma (HCC) glucose metabolism reprogramming and malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30671DOI Listing

Sorafenib Induces Pyroptosis in Macrophages and Triggers NK Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.

Hepatology 2019 Apr 19. Epub 2019 Apr 19.

Roche Innovation Center Munich, Roche Pharma Research and Early Development, Nonnenwald 2, 82377, Penzberg, Germany.

Antiangiogenic and cytotoxic effects are referred as the principle mechanisms of action of sorafenib, a multi-target kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). Here we report, that sorafenib also acts via direct immune-modulation indispensable for its anti-tumor activity. In vivo cell depletion experiments in two orthotopic HCC mouse models as well as in vitro analysis identified macrophages (MΦ) as the key mediators of the anti-tumoral effect and demonstrate a strong interdependency of MΦ and natural killer (NK) cells for efficient tumor cell killing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30666DOI Listing

External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation.

Hepatology 2019 Apr 19. Epub 2019 Apr 19.

Baylor University Medical Center, Dallas, TX, United States.

In patients with end stage liver disease, the ability to predict recovery of renal function following liver transplantation alone (LTA) remains elusive. However, several important clinical decisions depend on whether renal dysfunction is recoverable after LTA. We used a cohort of patients undergoing LT to independently validate a pre-LT model predictive of post-LTA renal recovery (REVERSE: high osteopontin (OPN) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels, age <57, no diabetes). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30667
Publisher Site
http://dx.doi.org/10.1002/hep.30667DOI Listing
April 2019
1 Read

The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials.

Hepatology 2019 Apr 16. Epub 2019 Apr 16.

Inova Fairfax Hospital, Falls Church, Virginia.

Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 NASH patients with bridging fibrosis (F3) or compensated cirrhosis (F4) enrolled in 2 phase 2b, placebo-controlled trials of simtuzumab. The trials were terminated after 96 weeks due to lack of efficacy, so data from treatment groups were combined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30664DOI Listing

The evaluation of cGAS-STING pathway expression in vivo.

Authors:
Mingyuan Zhang

Hepatology 2019 Apr 16. Epub 2019 Apr 16.

Xinmin Street NO.71, Changchun, China, 130021.

We read the recent article by Eloi R. Verrier et al(1) titled "Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes" with great interest. The authors have shown that cGAS is expressed in the human liver, primary human hepatocytes and human liver chimeric mouse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30665DOI Listing
April 2019
5 Reads

HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.

Hepatology 2019 Apr 16. Epub 2019 Apr 16.

Department of Pathology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.

Histone deacetylase 6 (HDAC6) uniquely endows as tumor suppressor in hepatocellular carcinogenesis, but the underlying mechanisms leading to tumor suppression are not fully understood. To identify comprehensive microRNAs (miRNAs) regulated by HDAC6 in hepatocellular carcinogenesis, differential miRNA expression analysis of HDAC6-transfected Hep3B cells was performed. Using integrative analyses of publicly available transcriptome data and miRNA target prediction, we selected 5 candidate miRNAs and, through in vitro functional validation, showed that let-7i-5p specifically suppressed thrombospondin-1 (TSP1) in hepatocellular carcinoma (HCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30657DOI Listing
April 2019
1 Read

Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis.

Hepatology 2019 Apr 16. Epub 2019 Apr 16.

Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT., USA.

There is an urgent need for practical approaches to patients with non-alcoholic steatohepatitis (NASH). Total body weight loss (TBWL) is an important approach because its effects are amplified in the liver, with 10% TBWL resulting in a 50% loss of liver triglycerides, and improvement in all aspects of NASH histology. Lifestyle changes are the first step in addressing TBWL, but uncommonly result in the range (7-10%) required to improve liver histology in NASH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30658DOI Listing

Response to « The evaluation of cGAS-STING pathway expression in vivo ».

Hepatology 2019 Apr 16. Epub 2019 Apr 16.

Université de Strasbourg, Inserm Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, F-67000, Strasbourg, France.

We would like to thank Dr. Zhang for the comment on our article « Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes » (1).First, we would like to address the question regarding the role of the immune system in the human liver chimeric mouse model. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30663
Publisher Site
http://dx.doi.org/10.1002/hep.30663DOI Listing
April 2019
1 Read

Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.

Hepatology 2019 Apr 15. Epub 2019 Apr 15.

Department of Microbiology and Immunology and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Activation of hepatic stellate cells (HSCs) represents the primary driving force to promote the progression of chronic cholestatic liver diseases. We previously reported that cholangiocyte-derived exosomal-long non-coding RNA-H19 (LncRNA-H19) plays a critical role in promoting cholestatic liver injury. However, it remains unclear whether cholangiocyte-derived lncRNA-H19 regulates HSC activation, which is the major focus of this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30662DOI Listing
April 2019
1 Read

HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans.

Hepatology 2019 Apr 15. Epub 2019 Apr 15.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P.R. China.

Polygonum multiflorum (PM) is a well-known Chinese herbal medicine that has been reported to induce inflammation-associated idiosyncratic liver injury. This study aimed to identify the genetic basis of susceptibility to PM-drug-induced liver injury (PM-DILI) and to develop biological markers for predicting the risk of PM-DILI in humans. The major histocompatibility complex (MHC) regions of 11 patients with PM-DILI were sequenced, and all human leukocyte antigen (HLA)-type frequencies were compared to the Han-MHC database. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30660
Publisher Site
http://dx.doi.org/10.1002/hep.30660DOI Listing
April 2019
7 Reads

Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis.

Hepatology 2019 Apr 15. Epub 2019 Apr 15.

Maternal and Fetal Disease Group, Women and Children's Health Division, King's College London, London, SE1 1UL, UK.

Pregnancy is associated with progressive hypercholanemia, hypercholesterolemia and hypertriglyceridemia, which can result in metabolic disease in susceptible women. Gut signals modify hepatic homeostatic pathways, linking intestinal content to metabolic activity. We sought to identify whether enteric endocrine signals contribute to raised serum bile acids observed in human and murine pregnancies, by measuring fibroblast growth factor (FGF)19/15 protein and mRNA levels, and 7α-hydroxy-4-cholesten-3-one. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30661DOI Listing

Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy.

Hepatology 2019 Apr 10. Epub 2019 Apr 10.

Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL, University of Salamanca, Salamanca, Spain.

Although the multi-tyrosine kinase inhibitor, sorafenib is useful in the treatment of several cancers, cholangiocarcinoma (CCA) is refractory to this drug. Among other mechanisms of chemoresistance impaired uptake via hOCT1 (gene SLC22A1) has been suggested. Here we have investigated the events accounting for this phenotypic characteristic and have evaluated the interest of selective gene therapy strategies to overcome this limitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30656DOI Listing
April 2019
1 Read

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Hepatology 2019 Apr 9. Epub 2019 Apr 9.

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre.

Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to control HCV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30647DOI Listing
April 2019
1 Read

Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation.

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Norris Comprehensive Cancer Center and Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Telomeres are repetitive DNA sequences that protect the ends of linear chromosomes, and they are maintained by a ribonucleoprotein complex called telomerase. Variants in genes encoding for telomerase components have been associated with a spectrum of disease in the lung, skin, bone marrow, and liver. Mutations in the telomerase reverse transcriptase and telomerase RNA component genes have been observed at a higher prevalence in patients with liver disease compared with the general population; however, the presence of variants in other components of the telomerase complex and their impact on clinical outcomes has not been explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30557DOI Listing
February 2019
1 Read

Immunetolerant Hepatitis B: Maybe a misnomer but still hard to treat.

Authors:
Paul Martin

Hepatology 2019 Apr 9. Epub 2019 Apr 9.

Division of Gastroenterology and Hepatology, Miller School of Medicine, University of Miami, Miami, FL, 33136.

An unresolved issue in the management of chronic hepatitis B (HBV) infection has been the role of antiviral therapy in the large number of younger patients infected at an early age with active viral replication and HBeAg positivity without biochemical abnormalities, felt to reflect an immune tolerant (IT)) state without progressive liver injury. The recent AASLD Guidance document defines the IT phase as absence of biochemical dysfunction (ALT < 35 U/l in men, < 25 U/L in women), presence of HBeAg, elevated HBV DNA > 1 million IU/L and minimal inflammation with an absence of fibrosis The authors however also suggest that if ALT levels are borderline normal or mildly elevated evaluation of hepatic fibrosis and inflammation especially in patients > 40 years with childhood acquired HBV infection be undertaken by liver biopsy or elastography to determine need for antiviral therapy. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30654DOI Listing

MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes.

Hepatology 2019 Apr 9. Epub 2019 Apr 9.

Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA.

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from simple steatosis to more severe forms of liver injury including nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). In humans, only 20-40% of patients with fatty liver progress to NASH, and mice fed a high-fed diet (HFD) develop fatty liver but are resistant to NASH development. To understand how simple steatosis progresses to NASH, we examined hepatic expression of anti-inflammatory microRNA-223 (miR-223) and found that this miRNA was highly elevated in hepatocytes in HFD-fed mice and in human NASH samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30645DOI Listing
April 2019
4 Reads

BMP9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting from hepatic fibrosis.

Hepatology 2019 Apr 9. Epub 2019 Apr 9.

Univ. Grenoble Alpes, Inserm, CEA, BCI Laboratory, Grenoble, France.

Bone morphogenetic protein 9 (BMP9) is a circulating factor produced by hepatic stellate cells that plays a critical role in vascular quiescence via its endothelial receptor ALK1. Mutations in the gene encoding ALK1 cause HHT2 (Hereditary Hemoragic Telangiectasia type 2), a rare genetic disease presenting hepatic vessel malformations. Variations of both the circulating levels and the hepatic mRNA levels of BMP9 have been recently associated with various forms of hepatic fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30655DOI Listing

A novel bioreactor technology for modelling fibrosis in human and rodent precision-cut liver slices.

Hepatology 2019 Apr 4. Epub 2019 Apr 4.

Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Precision cut liver slices (PCLS) retain the structure and cellular composition of the native liver and represent an improved system to study liver fibrosis compared to two-dimensional mono or co-cultures. The aim of this study was to develop a bioreactor system to increase the healthy lifespan of PCLS and model fibrogenesis. PCLS were generated from normal rat or human liver, or fibrotic rat liver and cultured in our bioreactor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30651DOI Listing
April 2019
1 Read

Reply to Letter from Yan and colleagues.

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Mayo Clinic Gastroenterology and Hepatology, Rochester, MN, USA.

We thank Yan and colleagues for their interest in our study and for their comments.(1) Placebo effect in medicine has been well known and documented.(2, 3) However, the main effect of placebo is observed in patient-reported outcomes or subjective measures; the effect of placebo on objective biomarkers or hard outcomes such as mortality are likely minimal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30648DOI Listing

A frizzled-like cysteine rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice.

Hepatology 2019 Apr 9. Epub 2019 Apr 9.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Wnt signaling is one of the key regulators of hepatocellular carcinoma (HCC) tumor progression. In addition to the classical receptor frizzled (FZD), various co-receptors including heparan sulfate proteoglycans (HSPGs) are involved in Wnt activation. Glypican-3 (GPC3) is a HSPG that is overexpressed in HCC and functions as a Wnt co-receptor that modulates HCC cell proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30646DOI Listing
April 2019
1 Read

Fructose Promotes Leaky Gut, Endotoxemia and Liver Fibrosis through CYP2E1-Mediated Oxidative and Nitrative Stress.

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA.

Fructose intake is known to induce obesity, insulin resistance, metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). We aimed to evaluate the effects of fructose drinking on gut leakiness, endotoxemia, and NAFLD and study the underlying mechanisms in rats, mice, and T84 colon cells. The levels of ileum junctional proteins, oxidative stress markers and apoptosis-related proteins in rodents, T84 colonic cells and human ileums were determined by immunoblot, immunoprecipitation, and immunofluorescence analyses. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30652
Publisher Site
http://dx.doi.org/10.1002/hep.30652DOI Listing
April 2019
5 Reads

Comment on Qiao et al.

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Institut Cochin, Paris Descartes University, Paris, France.

We read with great interest the article entitled « Axin1 deletion induced hepatocarcinogenesis requires intact β-catenin but not Notch cascade in mice" published in the February issue of Hepatology (1). The findings of this study corroborate our previous data that the in vivo deletion of Axin1 in hepatocytes using conditional knock-out mice does not result in classical activation of the Wnt/β-catenin pathway but leads to development of hepatocellular carcinomas (HCC) (2). This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30650DOI Listing
April 2019
1 Read

To the editor: Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Endoscopy Center for Diagnosis and Treatment, Taipei Veterans General Hospital.

We read the paper by Nardelli et al with great interest. The study tried to establish the correlation between using of proton pump inhibitors (PPIs) and the occurrence of minimal/overt hepatic encephalopathy (HE) among cirrhotics. In accordance with our previous retrospective population study, Nardelli et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30641DOI Listing
April 2019
5 Reads

Reply (to LTE HEP-19-0392).

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Universitätsmedizin Greifswald, Institute of Pathology, Friedrich-Löffler-Str. 23e, Greifswald, Germany.

We thank Drs. Gilgenkrantz and Perret for their insightful comments on the manuscript by Qiao Y et al . In agreement with their comments, we believe that all conclusions in our study are based on the experimental system used, including human tumor samples, cell lines and mouse models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30644DOI Listing
April 2019
3 Reads

A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC).

Hepatology 2019 Apr 8. Epub 2019 Apr 8.

Division of Medical Oncology, Departments of Medicine and Pathology, Stanford University, CA, Stanford, USA.

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in developed countries and its incidence is rapidly increasing. Cirrhosis, and the dreaded complication of hepatocellular carcinoma (HCC), are the major drivers of morbidity and mortality in NASH. Conventional understanding has been that chronic liver damage leads to a cycle of cell death, regeneration and fibrosis during which HCC precursor cells undergo malignant transformation and lead to cancer initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30649DOI Listing

HEP-18-0797.R2 - Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.

Hepatology 2019 Apr 5. Epub 2019 Apr 5.

Indiana University, Medicine.

We appreciate the interest and the thoughtful response by Gioia et al. on our recent observations about the liver stiffness measurement in patients with non-cirrhotic portal hypertension (NCPH). The causes of NCPH are myriad and can be prehepatic, hepatic or post hepatic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30640DOI Listing
April 2019
3 Reads

Proton pump inhibitors in cirrhosis: a marker of morbid conditions or cause of mortality.

Hepatology 2019 Apr 5. Epub 2019 Apr 5.

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

We read with interest the study by Nardelli et al., which adds to a growing literature on the potential ills of proton pump inhibitors (PPIs) in patients with cirrhosis. Their prospective design allowed for assessment of minimal HE (MHE) and they reported that PPI use was independently associated with MHE, overt HE and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30642DOI Listing
April 2019
1 Read

Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis.

Hepatology 2019 Apr 4. Epub 2019 Apr 4.

UT Southwestern Medical Center, Department of Internal Medicine, Dallas, Texas.

Background: Hepatitis C virus (HCV) testing in persons born from 1945 to 1965 has had limited adoption despite guidelines, particularly among racial/ethnic minorities and socioeconomically disadvantaged patients, who have a higher prevalence of disease burden. We examined the effectiveness of a multifaceted intervention to improve HCV screening in a large safety-net health system.

Methods: We performed a multifaceted intervention that included provider and patient education, an EMR-enabled best practice alert, and increased HCV treatment capacity. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30638
Publisher Site
http://dx.doi.org/10.1002/hep.30638DOI Listing
April 2019
8 Reads
11.055 Impact Factor

Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs.

Hepatology 2019 Apr 4. Epub 2019 Apr 4.

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.

Among the 250,000 homeless Veterans (HVs) that receive care in the Veterans Health Administration (VA), 13.4% have chronic hepatitis C virus (HCV) infection(1). As of 2015, only 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30643DOI Listing
April 2019
2 Reads

PPIs in cirrhosis: more evidences for a careful prescription!

Hepatology 2019 Apr 4. Epub 2019 Apr 4.

Universita di Roma La Sapienza, Dipartimento di Medicine Clinica.

We thank Yu-Jen Chen and Andrew M. Moon for their interest in our study . Their comments are extremely stimulating and appropriate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30639DOI Listing
April 2019
3 Reads

Reply to HCV prevalence estimates among incarcerated persons (Letter to the Editor regarding HEP-18-1268.R1).

Hepatology 2019 Apr 4. Epub 2019 Apr 4.

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.

We appreciate Dr. Spaulding and colleagues' thoughtful commentary on our article. We used national data to provide the most accurate estimate possible of the prevalence of hepatitis C among adults in the United States, but our estimate was dependent on the quality and completeness of the available data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30635DOI Listing
April 2019
1 Read

Characteristics of impaired dendritic cell function in patients with hepatitis B virus infection.

Hepatology 2019 Apr 2. Epub 2019 Apr 2.

Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Ishikawa, 920-8641, Japan.

Dendritic cells are antigen-presenting cells with a central role in host immune response. This study analyzed gene expression and dendritic cell function in hepatitis B virus (HBV) patients, functions impaired due to HBV, and identified the genes related to these functions. Peripheral blood mononuclear cells from 64 HBV patients and 19 healthy controls were analyzed. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30637
Publisher Site
http://dx.doi.org/10.1002/hep.30637DOI Listing
April 2019
2 Reads

HCV prevalence estimates among incarcerated persons.

Hepatology 2019 Apr 2. Epub 2019 Apr 2.

Georgia State University, Criminology and Criminal Justice.

Hofmeister identified populations with heightened HCV prevalence, including 2.1M individuals incarcerated 12/31/16(1), estimating this population's HCV prevalence at 9.5x that of householders surveyed by the National Health and Nutrition Epidemiology Survey (NHANES). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30636DOI Listing
April 2019
11.055 Impact Factor

Gallbladder dyskinesia is associated with an impaired postprandial FGF19 response in critically ill patients.

Hepatology 2019 Apr 1. Epub 2019 Apr 1.

Department of Surgery, Maastricht University Medical Center and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.

Critical illness is associated with a disturbed regulation of gastrointestinal hormones resulting in functional and metabolic anomalies. FGF19 is an ileum-derived metabolic hormone induced by bile salts upon gallbladder emptying after enteral nutrient stimulation. Our aim was to study the nutrient-stimulated FGF19 response in 24 patients admitted to the intensive care unit (ICU) compared with 12 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30629DOI Listing

HNF4A is essential for the active epigenetic state at enhancers in mouse liver.

Hepatology 2019 Apr 1. Epub 2019 Apr 1.

Terry Fox Laboratory, BC Cancer, Vancouver, British Columbia, Canada, V5Z 1L3.

Cell fate determination is influenced by interactions between master transcription factors (TFs) and cis-regulatory elements. Hepatocyte nuclear factor 4 alpha (HNF4A), a liver-enriched TF, acts as a master controller in specification of hepatic progenitor cells by regulating a network of TFs to control the onset of hepatocyte cell fate. Using analysis of genome-wide histone modifications, DNA methylation and hydroxymethylation in mouse hepatocytes, we show that HNF4A occupies active enhancers in hepatocytes and is essential for active histone and DNA signatures, especially H3K27ac and 5-hydroxymethylcytosine (5hmC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30631DOI Listing

A Positive Feedback Loop between Cancer Stem-Like Cells and Tumor- Associated Neutrophils Controls Hepatocellular Carcinoma Progression.

Hepatology 2019 Apr 1. Epub 2019 Apr 1.

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Institute of Biomedical Sciences Fudan University, Shanghai, 200032, China.

Tumor-associated neutrophils (TANs) play a crucial role in tumor development and progression in the cancer microenvironment. Despite increased understanding of TAN contributions to hepatocellular carcinoma (HCC) progression and prognosis, the direct interaction between TANs and HCC cells is not fully understood. In this study, we tested the effect of TANs on HCC cells in vitro and in vivo and investigated the mechanism of interaction between them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30630DOI Listing
April 2019
4 Reads

Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.

Hepatology 2019 Mar 30. Epub 2019 Mar 30.

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Although patients undergo procedures with curative intent for early stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune based therapies in the adjuvant setting for HCC focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune based therapy and what type of immune therapy should be implemented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30633DOI Listing

Reply to comment: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma.

Hepatology 2019 Mar 30. Epub 2019 Mar 30.

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

We appreciate the comments by Lai on our study. We completely agree that proton pump inhibitor (PPI) use is not associated with an increased risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B or C. However, another recent nested case-control study using the Taiwan National Health Insurance (NHI) database showed that PPI use might increase the risk of HCC in patients without hepatitis B or C infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30632DOI Listing
March 2019
2 Reads

Sex Differences in NAFLD: State of the Art and Identification of Research Gaps.

Hepatology 2019 Mar 29. Epub 2019 Mar 29.

Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA.

In spite of tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex-differences in NAFLD remains insufficient. This review summarizes current knowledge on sex differences in NAFLD, identifies current gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30626DOI Listing
March 2019
2 Reads

Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study.

Hepatology 2019 Mar 29. Epub 2019 Mar 29.

Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, DHU Unity, Pôle des Maladies de l'Appareil Digestif, Hôpital Beaujon, AP-HP, Clichy, France.

In patients with idiopathic noncirrhotic portal hypertension (INCPH), data on morbi-mortality of abdominal surgery are scarce We retrospectively analyzed the charts of patients with INCPH undergoing abdominal surgery within the VALDIG network. Forty-four patients with biopsy-proven INCPH were included. Twenty-five (57%) patients had ≥1 extrahepatic conditions related with INCPH and 16 (36%) had a history of ascites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30628DOI Listing
March 2019
1 Read

Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD.

Hepatology 2019 Mar 26. Epub 2019 Mar 26.

Hepatology, Gastroenterology and Nutrition Unit, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.

Emerging evidence suggests that patatin-like phospholipase domain-containing protein-3 (PNPLA3) rs738409 genotype (the major genetic variant associated with susceptibility to non-alcoholic fatty liver disease [NAFLD]) is associated with decreased kidney function in adults. Currently, it is uncertain whether this association also occurs in children/adolescents and whether any association is independent of liver disease severity. We enrolled a sample of 142 consecutive Caucasian children and adolescents with biopsy-proven NAFLD, presenting to the Liver Unit of the "Bambino Gesù" Children's Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30625DOI Listing
March 2019
1 Read

Expanding and Underscoring the Hepato-Encephalopathic Phenotype of QIL1/MIC13.

Hepatology 2019 Mar 26. Epub 2019 Mar 26.

Robert Debré Hospital, University Paris Diderot-Sorbonne Paris Cité, APHP, Reference Center for Inherited Metabolic Diseases, Paris, FR.

Mitochondrial disease is concerning with rapid infantile liver failure. Two sibling pairs with variants in QIL1, a gene important for mitochondrial contact site and cristae organizing system (MICOS) function, were recently reported. They had intermittent liver disease, mild cardiac hypertrophy, cerebellar atrophy, acquired microcephaly, neurologic impairment and death before age 5 (12mo-5yo). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30627DOI Listing
March 2019
3 Reads